Seeking AlphaQwen · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 21:24:28(美东 09:24)·⟳ 抓取 21:24:38 +10s·⚡ 决策 09-03 21:28:12 +3m34s·54.1 天前
AbbVie完成109亿美元收购Apogee Therapeutics，重申2026年EPS指引
交易于2026年6月由FT首次报道，本次仅为程序性交割完成；指引重申而非上调，EPS稀释幅度在预期内；对超大市值ABBV无可交易增量信息，APGE交割后不再独立上市。
📄 原文Seeking Alpha↗ 原文
AbbVie seals $11B acquisition of Apogee Therapeutics
AbbVie ( ABBV ) has completed its $10.9 billion acquisition of Apogee Therapeutics ( APGE ), the company said on Thursd…
不做 AbbVie（ABBV.US）
超大市值（~$350B）已公布并购的程序性交割完成，6月FT首报后市场已充分定价；指引重申而非上调，EPS稀释已含在原有指引中，无新增可交易增量信息。
不做 Apogee Therapeutics（APGE.US）
收购交割完成后Apogee不再独立上市交易，无可执行标的。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
AbbVie完成6月已公布的109亿美元Apogee收购交割，属并购最后程序性步骤。指引重申（非上调）且稀释影响已含在原有指引中，无新增财务或管线信息。对~$350B市值的ABBV，交割本身不构成短线催化；APGE交割后不再独立交易。无二阶受益标的（竞争格局未因交割本身改变）。
🔎 新鲜度:最早出现 2026-06-01 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:先例不适用于本判断——事件本身无可交易增量
方向:无需先例：程序性交割无增量信息，不构成可交易事件
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 722 ms
{"result": "search_processed_events:agent query=`abbv apge deal closing $10.9 billion | abbvie 2026 eps guidance reaffirmed | abbvie apogee therapeutics acquisition completed`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7340 条本臂决策(完整)，返回 5 条候选。\n• 09-03 13:03 UTC(CST 21:03) [ticker] 不做 ABBV.US (wire) — AbbV
原文全文
展开原文 · 949 字
AbbVie ( ABBV ) has completed its $10.9 billion acquisition of Apogee Therapeutics ( APGE ), the company said on Thursday. The deal, which is the pharma giant's largest bolt-on acquisition since 2019, was first reported by The Financial Times in June. AbbVie expects its acquisition to negatively impact adjusted diluted earnings per share by $0.14 in 2026 (partial year) and ~$0.46 in 2027, with accretion beginning in 2032. The company has reaffirmed its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07 (vs. consensus of $14.01). This guidance includes a $0.14 per share dilutive impact related to the completed Apogee acquisition. The EPS guidance also includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter. It also reaffirmed its Q3 adjusted EPS guidance in the range of $3.84 - $3.88 (vs. consensus of $3.84).
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。